What are the treatment options for Supraventricular Tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Supraventricular Tachycardia (SVT)

Begin with vagal maneuvers as first-line treatment, specifically the modified Valsalva maneuver in the supine position with legs raised, followed by adenosine 6 mg IV push if vagal maneuvers fail, and proceed to synchronized cardioversion for hemodynamically unstable patients. 1, 2, 3

Acute Management Algorithm

Step 1: Vagal Maneuvers (First-Line)

  • Perform the modified Valsalva maneuver: Patient bears down against a closed glottis for 10-30 seconds (equivalent to 30-40 mm Hg intrathoracic pressure), then immediately lies flat with legs raised 1, 2, 4
  • The modified technique achieves 43% conversion rate compared to only 17% with standard Valsalva 4, 5
  • Alternative vagal maneuvers include carotid sinus massage (5-10 seconds of steady pressure after confirming absence of bruit) or applying ice-cold wet towel to face 1, 3
  • Switching between vagal maneuver techniques increases overall success to 27.7% 1, 3
  • Critical pitfall: Never apply pressure to the eyeball—this practice is dangerous and abandoned 3

Step 2: Adenosine (First-Line Medication)

  • Administer 6 mg rapid IV bolus through large antecubital vein followed by 20 mL saline flush 1, 2
  • If no conversion within 1-2 minutes, give 12 mg rapid IV push 1
  • Adenosine terminates AVNRT in 90-95% of patients 1, 2, 3
  • Dose adjustments: Reduce initial dose to 3 mg in patients taking dipyridamole or carbamazepine, those with transplanted hearts, or if given by central venous access 1
  • Larger doses may be required for patients with significant theophylline, caffeine, or theobromine levels 1
  • Contraindication: Do not give to patients with asthma 1
  • Have defibrillator available when administering adenosine due to possibility of initiating atrial fibrillation with rapid ventricular rates in patients with WPW 1

Step 3: Alternative Pharmacologic Agents (If Adenosine Fails)

  • IV diltiazem or verapamil are particularly effective for converting AVNRT to sinus rhythm in hemodynamically stable patients 1, 3
  • IV beta blockers are reasonable but less effective than calcium channel blockers 1, 3
  • Critical contraindications: Avoid diltiazem, verapamil, and beta blockers in patients with suspected VT, pre-excited AF, or systolic heart failure—these patients may develop ventricular fibrillation 1, 3

Step 4: Synchronized Cardioversion

  • For hemodynamically unstable patients: Perform synchronized cardioversion immediately when adenosine and vagal maneuvers fail or are not feasible 1, 3
  • For hemodynamically stable patients: Use synchronized cardioversion when pharmacological therapy fails or is contraindicated 1
  • Initial biphasic energy dose: 50-100 J for SVT (120-200 J for atrial fibrillation), increase stepwise if initial shock fails 1
  • Monophasic waveforms should begin at 200 J 1

Special Populations and Considerations

Pre-Excitation/WPW Syndrome

  • Avoid all AV nodal blocking agents (verapamil, diltiazem, beta-blockers, adenosine for sustained arrhythmias) as they may accelerate ventricular rate and cause ventricular fibrillation 3
  • For hemodynamically stable pre-excited AF: Use IV procainamide or ibutilide 2, 3
  • For hemodynamically unstable pre-excited AF: Immediate synchronized cardioversion 3

Pregnancy

  • Vagal maneuvers remain safe and first-line 2
  • Adenosine is safe due to short half-life 2
  • Synchronized cardioversion can be performed safely at all stages of pregnancy if necessary 2

Long-Term Management

Pharmacologic Prevention

  • Beta blockers are first-line for long-term prevention of recurrent SVT 2, 3
  • Calcium channel blockers (diltiazem or verapamil) are alternative first-line agents 2, 3
  • For patients without structural heart disease who are not ablation candidates: Flecainide or propafenone are reasonable alternatives 3, 6
  • Critical warning: Flecainide has proarrhythmic effects (13-26% incidence in sustained VT patients) and should be reserved for patients without structural heart disease, recent MI, or chronic atrial fibrillation 6

Catheter Ablation (Definitive Treatment)

  • Curative option with high success rates and low complication frequency 2, 3
  • Indications include: frequent symptomatic episodes, poor medication tolerance or ineffectiveness, patient preference for non-pharmacological approach, or occupational requirements 2, 3
  • Provides potential cure without need for chronic pharmacological therapy 3

Patient Education

  • Teach proper vagal maneuver techniques for self-management of future episodes 3
  • Specifically instruct on modified Valsalva: forcefully exhale against closed airway for 10-30 seconds in supine position, then lie flat with legs raised 2, 3

Critical Diagnostic Caveat

  • Always obtain 12-lead ECG to differentiate tachycardia mechanisms before treatment 2, 3
  • Essential to distinguish SVT with aberrancy from ventricular tachycardia before initiating treatment 2
  • Automatic tachycardias (ectopic atrial tachycardia, MAT, junctional tachycardia) are not responsive to cardioversion and require rate control with AV nodal blocking agents 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Supraventricular Tachycardia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Supraventricular Tachycardia Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.